TABLE 3.
Summary of demographics for subjects receiving tafenoquine and included in the time-to-event exposure-response analysis
| Parameter | Value (means [SD]) | Category | No. (%) |
|---|---|---|---|
| AUC (μg · h/ml) | 59.0a (49.1, 68.9) | ||
| Age (yr) | 35.7 (14.1) | ||
| Weight (kg) | 60.0 (11.8) | ||
| BMI (kg/m2) | 23.5 (4.44) | ||
| Time of initial parasite clearance (day) | 2 (1–6) | ||
| Time of relapse (day) | 86b (38–172) | ||
| Status | Relapsed (event) | 51 (28) | |
| Relapse free (censored) | 129 (72) | ||
| Gender | Male | 140 (78) | |
| Female | 40 (22) | ||
| Baseline parasitemia count | ≤7,500/μl | 125 (70) | |
| >7,500/μl | 55 (30) | ||
| Country | Brazil | 25 (14) | |
| Peru | 90 (50) | ||
| Thailand | 65 (36) | ||
| Dose | 50 mg | 43 (23.9) | |
| 100 mg | 44 (24.4) | ||
| 300 mg | 47 (26.1) | ||
| 600 mg | 46 (25.6) |
a
Data are geometric means and 95% CI on untransformed data.
b
Median (range).